Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for use in the prophylactic management of asthma in adults and adolescents over 16 years of age.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 250 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 36.32 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation); fluticasone propionate, quantity: 125 microgram/actuation - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: - patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids. - patients who are symptomatic on current inhaled corticosteroid therapy.,for the symptomatic treatment of patients with severe copd (fev1 less than 50 precent predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. fluticasone propionate/salmeterol (125 microgram/25 microgram and 250 microgram/25 microgram) is not indicated for the initiation of bronchodilator therapy in copd.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 100ug;  ; umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg (free cation);  ; vilanterol trifenatate 40ug equivalent to 25 mcg of vilanterol (free base);   - powder for inhalation - active: fluticasone furoate 100ug   umeclidinium bromide 74.2ug equivalent to umeclidinium 62.5 mcg (free cation)   vilanterol trifenatate 40ug equivalent to 25 mcg of vilanterol (free base)   excipient: lactose monohydrate magnesium stearate - trelegy ellipta is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (copd) who require treatment with a long-acting muscarinic receptor antagonist (lama) + long-acting beta2-receptor agonist (laba) + inhaled corticosteroid (ics). trelegy ellipta should not be used for the initiation of copd treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone furoate 200ug;  ; umeclidinium bromide 74.2ug equivalent to 62.5 mcg of umeclidinium (free cation);  ; vilanterol trifenatate 40ug equivalent to 25 mcg of vilanterol (free base);   - powder for inhalation - active: fluticasone furoate 200ug   umeclidinium bromide 74.2ug equivalent to 62.5 mcg of umeclidinium (free cation)   vilanterol trifenatate 40ug equivalent to 25 mcg of vilanterol (free base)   excipient: lactose monohydrate magnesium stearate - trelegy ellipta is indicated for the maintenance treatment of asthma in adult patients who are not adequately controlled with a combination of inhaled corticosteroid and a long-acting beta2-agonist.

Canada - English - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 100mcg; 50mcg - fluticasone propionate 100mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Canada - English - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 250mcg; 50mcg - fluticasone propionate 250mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Canada - English - Health Canada

pharmascience inc - fluticasone propionate; salmeterol (salmeterol xinafoate) - powder - 500mcg; 50mcg - fluticasone propionate 500mcg; salmeterol (salmeterol xinafoate) 50mcg - adrenals

Canada - English - Health Canada

apotex inc - fluticasone propionate - metered-dose aerosol - 250mcg - fluticasone propionate 250mcg - adrenals

Canada - English - Health Canada

apotex inc - fluticasone propionate - metered-dose aerosol - 125mcg - fluticasone propionate 125mcg